Poractant Alfa Versus Beractant for Respiratory Distress Syndrome in Preterm Infants: a Retrospective Cohort Study
Aim: Poractant alfa and beractant are the commonly used animal derived surfactants in preterm infants with respiratory distress syndrome. Between 2005 and 2007, poractant alfa and beractant were alternated every month in our neonatal intensive care unit for 27 months. The aim of this study was to co...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Blackwell Scientific Publications
2013
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/14685 |
| _version_ | 1848748689104830464 |
|---|---|
| author | Paul, S. Rao, S. Kohan, R. McMichael, J. French, N. Zhang, Guicheng Simmer, K. |
| author_facet | Paul, S. Rao, S. Kohan, R. McMichael, J. French, N. Zhang, Guicheng Simmer, K. |
| author_sort | Paul, S. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Aim: Poractant alfa and beractant are the commonly used animal derived surfactants in preterm infants with respiratory distress syndrome. Between 2005 and 2007, poractant alfa and beractant were alternated every month in our neonatal intensive care unit for 27 months. The aim of this study was to compare the outcomes of preterm infants who received poractant alfa versus beractant. Method: Single-centre, retrospective cohort study of inborn preterm infants <32 weeks gestation (23–31+6). Results: Six hundred sixty-four preterm infants (<32 weeks) were born during the study period, of which 415 received surfactant (poractant alfa: 214; beractant: 201). Infants in the poractant alfa group were 2.8 days younger than beractant (27.0 2.3 vs. 27.4 2.3 weeks; P = 0.03). All other baseline characters including Clinical Risk Index for Babies II scores were similar for both groups. No significant differences were found for the following outcomes: death or chronic lung disease (78/212 vs. 59/200; P = 0.28); death (24/214 vs. 15/201, P = 0.24); moderate to severe chronic lung disease (63/212 vs. 46/200; P = 0.45) and moderate to severe disability (20/163 vs. 19/151, P = 0.98) between poractant alfa and beractant, respectively. Conclusions: The results of our study do not support the need for preferential use of poractant alfa or beractant. |
| first_indexed | 2025-11-14T07:09:02Z |
| format | Journal Article |
| id | curtin-20.500.11937-14685 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:09:02Z |
| publishDate | 2013 |
| publisher | Blackwell Scientific Publications |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-146852017-09-13T14:05:39Z Poractant Alfa Versus Beractant for Respiratory Distress Syndrome in Preterm Infants: a Retrospective Cohort Study Paul, S. Rao, S. Kohan, R. McMichael, J. French, N. Zhang, Guicheng Simmer, K. Chronic lung disease pulmonary surfactant premature infant respiratory distress syndrome Aim: Poractant alfa and beractant are the commonly used animal derived surfactants in preterm infants with respiratory distress syndrome. Between 2005 and 2007, poractant alfa and beractant were alternated every month in our neonatal intensive care unit for 27 months. The aim of this study was to compare the outcomes of preterm infants who received poractant alfa versus beractant. Method: Single-centre, retrospective cohort study of inborn preterm infants <32 weeks gestation (23–31+6). Results: Six hundred sixty-four preterm infants (<32 weeks) were born during the study period, of which 415 received surfactant (poractant alfa: 214; beractant: 201). Infants in the poractant alfa group were 2.8 days younger than beractant (27.0 2.3 vs. 27.4 2.3 weeks; P = 0.03). All other baseline characters including Clinical Risk Index for Babies II scores were similar for both groups. No significant differences were found for the following outcomes: death or chronic lung disease (78/212 vs. 59/200; P = 0.28); death (24/214 vs. 15/201, P = 0.24); moderate to severe chronic lung disease (63/212 vs. 46/200; P = 0.45) and moderate to severe disability (20/163 vs. 19/151, P = 0.98) between poractant alfa and beractant, respectively. Conclusions: The results of our study do not support the need for preferential use of poractant alfa or beractant. 2013 Journal Article http://hdl.handle.net/20.500.11937/14685 10.1111/jpc.12300 Blackwell Scientific Publications restricted |
| spellingShingle | Chronic lung disease pulmonary surfactant premature infant respiratory distress syndrome Paul, S. Rao, S. Kohan, R. McMichael, J. French, N. Zhang, Guicheng Simmer, K. Poractant Alfa Versus Beractant for Respiratory Distress Syndrome in Preterm Infants: a Retrospective Cohort Study |
| title | Poractant Alfa Versus Beractant for Respiratory Distress Syndrome in Preterm Infants: a Retrospective Cohort Study |
| title_full | Poractant Alfa Versus Beractant for Respiratory Distress Syndrome in Preterm Infants: a Retrospective Cohort Study |
| title_fullStr | Poractant Alfa Versus Beractant for Respiratory Distress Syndrome in Preterm Infants: a Retrospective Cohort Study |
| title_full_unstemmed | Poractant Alfa Versus Beractant for Respiratory Distress Syndrome in Preterm Infants: a Retrospective Cohort Study |
| title_short | Poractant Alfa Versus Beractant for Respiratory Distress Syndrome in Preterm Infants: a Retrospective Cohort Study |
| title_sort | poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study |
| topic | Chronic lung disease pulmonary surfactant premature infant respiratory distress syndrome |
| url | http://hdl.handle.net/20.500.11937/14685 |